Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following
DAA therapy
HCV
Sofosbuvir
antiviral therapy
liver disease
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
26
03
2019
accepted:
10
05
2019
entrez:
29
6
2019
pubmed:
30
6
2019
medline:
30
6
2019
Statut:
epublish
Résumé
Chronic hepatitis C virus (HCV) infection diminishes immune function through cell exhaustion and repertoire alteration. Direct acting antiviral (DAA)-based therapy can restore immune cell subset function and reduce exhaustion states. However, the extent of immune modulation following DAA-based therapy and the role that clinical and demographic factors play remain unknown. We examined natural killer (NK) cell, CD4 We show that Our study lends further evidence of immune changes following
Sections du résumé
BACKGROUND
BACKGROUND
Chronic hepatitis C virus (HCV) infection diminishes immune function through cell exhaustion and repertoire alteration. Direct acting antiviral (DAA)-based therapy can restore immune cell subset function and reduce exhaustion states. However, the extent of immune modulation following DAA-based therapy and the role that clinical and demographic factors play remain unknown.
METHODS
METHODS
We examined natural killer (NK) cell, CD4
RESULTS
RESULTS
We show that
CONCLUSION
CONCLUSIONS
Our study lends further evidence of immune changes following
Identifiants
pubmed: 31249845
doi: 10.1093/ofid/ofz223
pii: ofz223
pmc: PMC6589029
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz223Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103395
Pays : United States
Références
Science. 2004 Aug 6;305(5685):872-4
pubmed: 15297676
Am J Gastroenterol. 2004 Aug;99(8):1517-22
pubmed: 15307870
J Immunol. 2004 Nov 15;173(10):6072-81
pubmed: 15528343
J Virol. 2005 Jun;79(12):7860-7
pubmed: 15919940
J Virol. 2007 Sep;81(17):9249-58
pubmed: 17567698
Gut. 2008 Aug;57(8):1121-8
pubmed: 18372499
Nat Immunol. 2008 May;9(5):495-502
pubmed: 18425106
Gastroenterology. 2009 Sep;137(3):1151-60, 1160.e1-7
pubmed: 19470388
J Virol. 2009 Sep;83(18):9122-30
pubmed: 19587053
Cell. 2009 Jul 10;138(1):30-50
pubmed: 19596234
J Hepatol. 2009 Sep;51(3):458-67
pubmed: 19596474
J Hepatol. 2010 Mar;52(3):315-21
pubmed: 20129690
J Clin Invest. 2010 Dec;120(12):4546-57
pubmed: 21084749
Eur J Immunol. 2011 Oct;41(10):2905-14
pubmed: 21695691
Immunol Rev. 2013 Sep;255(1):68-81
pubmed: 23947348
Sci Transl Med. 2013 Oct 23;5(208):208ra145
pubmed: 24154599
Immunity. 2014 Jan 16;40(1):13-24
pubmed: 24439265
J Hepatol. 2014 Sep;61(3):538-43
pubmed: 24905492
Hepatology. 2015 Feb;61(2):712-21
pubmed: 25048716
J Hepatol. 2014 Nov;61(1 Suppl):S14-25
pubmed: 25443342
Cancer Cell. 2014 Dec 8;26(6):923-937
pubmed: 25465800
Cell. 2015 Jan 15;160(1-2):37-47
pubmed: 25594173
AIDS. 2015 Feb 20;29(4):463-71
pubmed: 25630041
J Infect Dis. 2015 Aug 1;212(3):386-90
pubmed: 25637348
Gastroenterology. 2015 Jul;149(1):190-200.e2
pubmed: 25754160
J Infect Dis. 2016 Jan 15;213(2):216-23
pubmed: 26223768
Antiviral Res. 2015 Nov;123:86-92
pubmed: 26363298
J Viral Hepat. 2015 Dec;22(12):983-91
pubmed: 26482547
Gastroenterol Clin North Am. 2015 Dec;44(4):717-34
pubmed: 26600216
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Eur J Immunol. 2016 Sep;46(9):2204-10
pubmed: 27296288
J Infect Dis. 2016 Dec 15;214(12):1965-1974
pubmed: 27683821
J Hepatol. 2017 May;66(5):888-896
pubmed: 28040549
Pharmacol Ther. 2018 Mar;183:118-126
pubmed: 29024739
Hepatol Commun. 2018 Mar 01;2(4):364-375
pubmed: 29619416
Nat Commun. 2018 Jun 11;9(1):2275
pubmed: 29891939
J Hepatol. 2019 May;70(5):874-884
pubmed: 30684506
Immunobiology. 1984 May;166(3):238-50
pubmed: 6329947
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650